Latest Healthcare News

Page 17 of 215
Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.
Ada Torres
Ada Torres
28 Apr 2026
Vitrafy Life Sciences completed Phase II of its U.S. Military platelet cryopreservation study with strong results for a simplified no-wash process, accelerating commercial interest and progressing FDA device registration despite manufacturing delays.
Ada Torres
Ada Torres
28 Apr 2026
EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.
Ada Torres
Ada Torres
28 Apr 2026
ECS Botanics reports a third straight quarter of positive operating cash flow, driven by strong B2C growth and strategic international shipments to Germany and New Zealand.
Ada Torres
Ada Torres
28 Apr 2026
TruScreen Group has met its FY2026 revenue guidance with a 41% jump in product sales, while investing heavily in new markets and pursuing a major UNITAID funding bid that could reshape its medium-term outlook.
Ada Torres
Ada Torres
28 Apr 2026
Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.
Ada Torres
Ada Torres
27 Apr 2026
PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.
Ada Torres
Ada Torres
27 Apr 2026
Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.
Ada Torres
Ada Torres
27 Apr 2026
Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.
Ada Torres
Ada Torres
27 Apr 2026
Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.
Ada Torres
Ada Torres
27 Apr 2026
The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.
Ada Torres
Ada Torres
27 Apr 2026
Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.
Ada Torres
Ada Torres
24 Apr 2026